Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Vassallo

Cardiovascular Disease Chevy Chase, MD Medical Doctor

NPI 1932106846 CMS profile 313932

5454 Wisconsin Ave, Suite 925, Chevy Chase, MD 20815

Open in the dashboard

General payments

$11,085

488 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Vassallo of Chevy Chase, MD is reported in the CMS Open Payments database as having received $11,085 across 488 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,232 53
2024 General $1,342 58
2023 General $1,749 70
2022 General $1,553 76
2021 General $2,027 92
2020 General $891 47
2019 General $2,291 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Vassallo
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Joseph Vassallo were reported at $1,232. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Joseph Vassallo Cardiovascular Disease median Middle half National median
2019 $2,291 $450 $127–$1,392 $163
2020 $891 $242 $77–$751 $114
2021 $2,027 $335 $101–$1,037 $132
2022 $1,553 $395 $121–$1,211 $149
2023 $1,749 $443 $136–$1,283 $160
2024 $1,342 $450 $136–$1,323 $164
2025 $1,232 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,107 51 payments
  2. Pfizer Inc. $1,048 55 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $988 38 payments
  4. Novartis Pharmaceuticals Corporation $929 45 payments
  5. Janssen Pharmaceuticals, Inc $887 31 payments
  6. E.R. Squibb & Sons, L.L.C. $861 36 payments
  7. Novo Nordisk Inc $624 18 payments
  8. Daiichi Sankyo Inc. $583 28 payments
  9. Esperion Therapeutics, Inc. $536 23 payments
  10. Amarin Pharma Inc. $433 24 payments
  11. Other $3,088 139 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,956 485 payments
  2. Education $129 3 payments
Products named General payments · program years 2019–2025
  1. XARELTO $887 31 payments
  2. Repatha $870 40 payments
  3. JARDIANCE $815 30 payments
  4. ELIQUIS Cardiovascular;Metabolic Disease $651 36 payments
  5. NEXLETOL $536 23 payments
  6. LEQVIO $456 21 payments
  7. ELIQUIS Cardiovascular $421 23 payments
  8. Corlanor $381 17 payments
  9. INJECTAFER $378 17 payments
  10. Vascepa $356 20 payments
  11. Other $6,821 310 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

6,242

Median for Cardiology: 2,533

Drug cost

$1,225,651

Median for Cardiology: $485,213

Branded share of claims

19.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 486 $678,709
Xarelto Rivaroxaban Brand 113 $167,501
Multaq Dronedarone Hcl Brand 49 $107,110
Entresto Sacubitril/Valsartan Brand 64 $91,362
Repatha Sureclick Evolocumab Brand 28 $43,059
Jardiance Empagliflozin Brand 19 $27,989
Edarbyclor Azilsartan Med/Chlorthalidone Brand 17 $11,799
Metoprolol Succinate Generic 659 $11,529
Atorvastatin Calcium Generic 820 $11,192
Nebivolol Hcl Generic 117 $7,110

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$509,348

Of which drugs: $5,982

Medicare patients

1,249

Average age 79

Services billed

7,426

613 women, 636 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 31%
Atrial fibrillation 30%
Diabetes 20%
Cancer 20%
Chronic kidney disease 16%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 11 12 $3,234
Injection, regadenoson, 0.1 mg J2785 Office 154 637 $2,490

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $125
$125 19 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $119
$119 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $103
$103 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $74
$74 — —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $74
$74 49 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

488 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record